Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (1607)
All Articles published online
|
Nov 14, 2007 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Braks RE, Ganne-Carrié N, Fontaine H, Paries J, Grando-Lemaire V, Beaugrand M, Pol S, Trinchet JC. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol 2007; 13(42): 5648-5653 [PMID: 17948941 DOI: 10.3748/wjg.v13.i42.5648] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v13/i42/5648.htm |
| Number | Citing Articles |
| 1 |
Ivan Gentile, Antonio Riccardo Buonomo, Guglielmo Borgia. Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection. Expert Review of Anti-infective Therapy 2014; 12(9): 1033 doi: 10.1586/14787210.2014.940898
|
| 2 |
Angelo Iacobellis, Angelo Andriulli. Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection. Expert Opinion on Pharmacotherapy 2009; 10(12): 1929 doi: 10.1517/14656560903066811
|
| 3 |
N. Jung, W.-J. Mayet, P.R. Mertens, J. Meyer (federführend), O.-A. Müller, M. Pfeifer, P. Schellinger, N. Weiss, C.-M. Wendtner. Rationelle Diagnostik und Therapie in der Inneren Medizin. 2020; : pA-1 doi: 10.1016/B978-3-437-06282-7.50008-5
|
| 4 |
Vivian Ng, Sammy Saab. Effects of a Sustained Virologic Response on Outcomes of Patients With Chronic Hepatitis C. Clinical Gastroenterology and Hepatology 2011; 9(11): 923 doi: 10.1016/j.cgh.2011.05.028
|
| 5 |
Norberto C. Chávez-Tapia, Ezequiel Ridruejo, Angelo Alves de Mattos, Fernando Bessone, Jorge Daruich, Juan F. Sánchez-Ávila, Hugo Cheinquer, Rodrigo Zapata, Misael Uribe, Francisco Bosques-Padilla, Adrián Gadano, Alejandro Soza, Milagros Dávalos-Moscol, Claudio Marroni, Linda Muñoz-Espinoza, Graciela Castro-Narro, Raymundo Paraná, Nahum Méndez-Sánchez. An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver. Annals of Hepatology 2013; 12: S3 doi: 10.1016/S1665-2681(19)31404-8
|
| 6 |
Lars Haukali Omland, Peter Jepsen, Henrik Krarup, Peer Brehm Christensen, Nina Weis, Lars Nielsen, Niels Obel, Henrik Toft Sørensen, Sherri Oliver Stuver. Liver cancer and non‐Hodgkin lymphoma in hepatitis C virus‐infected patients: Results from the DANVIR cohort study. International Journal of Cancer 2012; 130(10): 2310 doi: 10.1002/ijc.26283
|
| 7 |
Nahum Méndez-Sánchez, Adrian Gadano, Angelo Alves de Mattos, Alejandro Soza, Augusto Marroni Claudio, Marcela Galoppo, David Kershenobich, Edna Strauss, Eduardo Fassio, Gilberto Castañeda, Guillermo Valladares, Henrique Sergio Moraes Coelho, Jorge Daruich, Miguel Garassini, Milagros Dávalos, Misael Uribe, Maribel Rodriguez-Torres, Rodrigo Zapata, Marco Arrese, Francisco Sánchez-Ávila, Margarita Dehesa, Francisco Bosques Padilla, Paulo Roberto Lerias de Almeida, Mario Pessoa, Rocío Torres-Ibarra, Francisco Hevia, Miguel Contreras, Hugo Cheinquer. Latin American Association for the Study of the Liver Practice Guidelines. Annals of Hepatology 2010; 9: S8 doi: 10.1016/S1665-2681(19)31718-1
|
| 8 |
Amit G Singal, Purva Gopal, Adam C Yopp. Radiation Therapy for Liver Tumors. 2017; : 149 doi: 10.1007/978-3-319-54531-8_13
|
| 9 |
Alajos Pár. Prophylaxis and treatment of chronic viral hepatitis as the prevention of hepatocellular carcinoma. Orvosi Hetilap 2009; 150(1): 19 doi: 10.1556/oh.2009.28529
|
| 10 |
Nancy McGreal, Donald M. Jensen. Sustained viral response after interferon‐based therapy in chronic hepatitis C: more evidence to support a life‐long cure. Liver International 2009; 29(4): 481 doi: 10.1111/j.1478-3231.2009.02000.x
|
| 11 |
Joseph Ahn, Steven L. Flamm. Hepatitis C and hepatocellular carcinoma: New developments in natural history and treatment. Current Hepatitis Reports 2009; 8(2): 59 doi: 10.1007/s11901-009-0009-7
|
| 12 |
Kelly Fernanda Nomura DRESCH, Angelo Alves de MATTOS, Cristiane Valle TOVO, Fernanda Quadros de ONOFRIO, Leandro CASAGRANDE, Alberi Adolfo FELTRIN, Iago Christofoli de BARROS, Paulo Roberto Lerias de ALMEIDA. IMPACT OF THE PEGYLATED-INTERFERON AND RIBAVIRIN THERAPY ON THE TREATMENT-RELATED MORTALITY OF PATIENTS WITH CIRRHOSIS DUE TO HEPATITIS C VIRUS. Revista do Instituto de Medicina Tropical de São Paulo 2016; 58(0) doi: 10.1590/S1678-9946201658037
|
| 13 |
N. Merchante, M. Rodríguez-Fernández, J. A. Pineda. Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies. Current HIV/AIDS Reports 2020; 17(1): 6 doi: 10.1007/s11904-019-00475-0
|
| 14 |
Bryony Simmons, Jawaad Saleem, Katherine Heath, Graham S. Cooke, Andrew Hill. Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response. Clinical Infectious Diseases 2015; 61(5): 730 doi: 10.1093/cid/civ396
|
| 15 |
Vincent Mallet, Hélène Gilgenkrantz, Jeanne Serpaggi, Virginie Verkarre, Anaïs Vallet-Pichard, Hélène Fontaine, Stanislas Pol. Brief Communication: The Relationship of Regression of Cirrhosis to Outcome in Chronic Hepatitis C. Annals of Internal Medicine 2008; 149(6): 399 doi: 10.7326/0003-4819-149-6-200809160-00006
|
| 16 |
Hyun Jung Lee, Jong Eun Yeon, Eileen L. Yoon, Sang Jun Suh, Keunhee Kang, Hae Rim Kim, Seong Hee Kang, Yang Jae Yoo, Jihye Je, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Kwan Soo Byun. Long-Term Follow-Up of Chronic Hepatitis C Patients Treated with Interferon-Alpha: Risk of Cirrhosis and Hepatocellular Carcinoma in a Single Center over 10 Years. Intervirology 2015; 58(1): 14 doi: 10.1159/000369206
|
| 17 |
Nicolás Merchante, Esperanza Merino, Francisco Rodríguez-Arrondo, Cristina Tural, Josefa Muñoz, Marcial Delgado-Fernández, Francisco Jover, Maria J. Galindo, Antonio Rivero, José López-Aldeguer, Koldo Aguirrebengoa, Alberto Romero-Palacios, Eduardo Martínez, Juan A. Pineda. HIV/hepatitis C virus-coinfected patients who achieved sustained virological response are still at risk of developing hepatocellular carcinoma. AIDS 2014; 28(1): 41 doi: 10.1097/QAD.0000000000000005
|
| 18 |
Jayne Smith-Palmer, Karin Cerri, William Valentine. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infectious Diseases 2015; 15(1) doi: 10.1186/s12879-015-0748-8
|
| 19 |
Maria Pleguezuelo, Laura Marelli, Sergio Maimone, Pinelopi Manousou, Elias Xirouchakis, Andrew K. Burroughs. Does HCV antiviral therapy decrease the risk of hepatocellular carcinoma?. Current Hepatitis Reports 2008; 7(2): 72 doi: 10.1007/s11901-008-0011-5
|
| 20 |
Youngmin A. Lee, Scott L. Friedman. Reversal, maintenance or progression: What happens to the liver after a virologic cure of hepatitis C?. Antiviral Research 2014; 107: 23 doi: 10.1016/j.antiviral.2014.03.012
|
| 21 |
Ivan Gentile, Antonio Riccardo Buonomo, Emanuela Zappulo, Guglielmo Borgia. Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?. Expert Review of Anti-infective Therapy 2014; 12(7): 763 doi: 10.1586/14787210.2014.929497
|
| 22 |
Hellan Kwon, Anna S Lok. Does Antiviral Therapy Prevent Hepatocellular Carcinoma?. Antiviral Therapy 2011; 16(6): 787 doi: 10.3851/IMP1895
|
| 23 |
Andrew Aronsohn, Donald Jensen. HCV Eradication: Implications for Disease Resolution. Current Hepatitis Reports 2011; 10(1): 27 doi: 10.1007/s11901-010-0076-9
|
| 24 |
Kyung Hoon Kim, Byoung Kuk Jang, Woo Jin Chung, Jae Seok Hwang, Young Oh Kweon, Won Young Tak, Heon Ju Lee, Chang Hyeong Lee, Jeong Ill Suh. Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis. The Korean Journal of Hepatology 2011; 17(3): 220 doi: 10.3350/kjhep.2011.17.3.220
|
| 25 |
Ivan Gentile, Antonio Riccardo Buonomo, Federico Borgia, Emanuela Zappulo, Giuseppe Castaldo, Guglielmo Borgia. MK-5172: a second-generation protease inhibitor for the treatment of hepatitis C virus infection. Expert Opinion on Investigational Drugs 2014; 23(5): 719 doi: 10.1517/13543784.2014.902049
|
| 26 |
Ivan Gentile, Nicola Coppola, Antonio Riccardo Buonomo, Emanuela Zappulo, Guglielmo Borgia. Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. Expert Opinion on Investigational Drugs 2014; 23(9): 1211 doi: 10.1517/13543784.2014.921680
|
| 27 |
Andrea Messori, Brigitta Badiani, Sabrina Trippoli. Achieving Sustained Virological Response in Hepatitis C Reduces the Long-Term Risk of Hepatocellular Carcinoma: An Updated Meta-Analysis Employing Relative and Absolute Outcome Measures. Clinical Drug Investigation 2015; 35(12): 843 doi: 10.1007/s40261-015-0338-y
|
| 28 |
Andrew Aronsohn, Nancy Reau. Long-term Outcomes After Treatment With Interferon and Ribavirin in HCV Patients. Journal of Clinical Gastroenterology 2009; 43(7): 661 doi: 10.1097/MCG.0b013e31819f66e2
|
| 29 |
Ivan Gentile, Antonio Riccardo Buonomo, Emanuela Zappulo, Nicola Coppola, Guglielmo Borgia. GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection. Expert Review of Anti-infective Therapy 2014; 12(10): 1179 doi: 10.1586/14787210.2014.945432
|
| 30 |
Adriaan J. van der Meer, Jordan J. Feld, Harald Hofer, Piero L. Almasio, Vincenza Calvaruso, Conrado M. Fernández-Rodríguez, Soo Aleman, Nathalie Ganne-Carrié, Roberta D’Ambrosio, Stanislas Pol, Maria Trapero-Marugan, Raoel Maan, Ricardo Moreno-Otero, Vincent Mallet, Rolf Hultcrantz, Ola Weiland, Karoline Rutter, Vito Di Marco, Sonia Alonso, Savino Bruno, Massimo Colombo, Robert J. de Knegt, Bart J. Veldt, Bettina E. Hansen, Harry L.A. Janssen. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. Journal of Hepatology 2017; 66(3): 485 doi: 10.1016/j.jhep.2016.10.017
|
| 31 |
A. Striki, S. Manolakopoulos, M. Deutsch, M. Mela, M. Kalafateli, M. Schini, O. Anagnostou, C. Triantos, I. Andreadis, I. Ketikoglou, G. Papatheodoridis, D. Pectasides. Cirrhosis but not neutropenia is associated with the development of infection in patients with chronic hepatitis C undergoing treatment with pegylated interferon‐alpha and ribavirin. Journal of Viral Hepatitis 2014; 21(9): 624 doi: 10.1111/jvh.12197
|
| 32 |
Christoph R Werner, Carolin Franz, Daniel P Egetemeyr, Robert Beck, Nisar P Malek, Ulrich M Lauer, Christoph P Berg. First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort. Virology Journal 2015; 12(1) doi: 10.1186/s12985-015-0261-0
|
| 33 |
Shahana Prakash, Kyle Kinder, Kyle E Brown. Spleen size change after hepatitis C treatment: a simple parameter to predict clinical outcomes. Journal of Investigative Medicine 2023; 71(6): 603 doi: 10.1177/10815589231171403
|
| 34 |
David R. Nelson, Gary L. Davis, Ira Jacobson, Gregory T. Everson, Michael W. Fried, Stephen A. Harrison, Tarek Hassanein, Donald M. Jensen, Karen L. Lindsay, Norah Terrault, Nizar Zein. Hepatitis C Virus: A Critical Appraisal of Approaches to Therapy. Clinical Gastroenterology and Hepatology 2009; 7(4): 397 doi: 10.1016/j.cgh.2008.11.016
|
| 35 |
Shelagh M. Szabo, Jennifer C. Samp, David R. Walker, Suzanne Lane, Stephanie K. Cline, Katherine L. Gooch, Ricardo Jimenez-Mendez, Adrian R. Levy. Liver-specific case fatality due to chronic hepatitis C virus infection: A systematic review. Annals of Hepatology 2015; 14(5): 618 doi: 10.1016/S1665-2681(19)30756-2
|
| 36 |
Akira Sato, Kayo Adachi, Toshiya Ishii, Masayo Yamaguchi, Mika Kobayashi, Mikihito Hayashi, Miyako Tabashi, Masahito Nomoto, Akira Nikai. A case of Child-Pugh class B cirrhosis in hepatitis C infection successfully treated with interferon beta after balloon-occluded retrograde transvenous obliteration for gastric varices. Kanzo 2008; 49(7): 307 doi: 10.2957/kanzo.49.307
|
| 37 |
Ryota Higuchi, Hideki Yasuda, Keiji Koda, Masato Suzuki, Masato Yamazaki, Tohru Tezuka, Chihiro Kosugi, Atsushi Hirano, Shuichiro Uemura, Hironori Tsuchiya. . Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons) 2011; 36(1): 66 doi: 10.4030/jjcs.36.66
|
| 38 |
Christoph R Werner, Julia M Schwarz, Daniel P Egetemeyr, Robert Beck, Nisar P Malek, Ulrich M Lauer, Christoph P Berg. Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. World Journal of Gastroenterology 2016; 22(35): 8050-8059 doi: 10.3748/wjg.v22.i35.8050
|
| 39 |
R. Bielen, C. Moreno, H. Van Vlierberghe, S. Bourgeois, J.‐P. Mulkay, T. Vanwolleghem, W. Verlinden, C. Brixco, J. Decaestecker, C. de Galocsy, F. Janssens, L. Van Overbeke, C. Van Steenkiste, F. D'Heygere, M. Cool, K. Wuyckens, F. Nevens, G. Robaeys. The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C‐infected patients treated with direct‐acting antivirals with and without pegylated interferon: A Belgian experience. Journal of Viral Hepatitis 2017; 24(11): 976 doi: 10.1111/jvh.12726
|
| 40 |
B. L. Pearlman, N. Traub. Sustained Virologic Response to Antiviral Therapy for Chronic Hepatitis C Virus Infection: A Cure and So Much More. Clinical Infectious Diseases 2011; 52(7): 889 doi: 10.1093/cid/cir076
|
| 41 |
Amit Singal, Jorge A. Marrero. Yamada' s Textbook of Gastroenterology. 2015; : 2146 doi: 10.1002/9781118512074.ch109
|
| 42 |
Nicolás Merchante, Antonio Rivero-Juárez, Francisco Téllez, Dolores Merino, María J Ríos-Villegas, Marina Villalobos, Mohamed Omar, Pilar Rincón, Antonio Rivero, Montserrat Pérez-Pérez, Miguel Raffo, Inmaculada López-Montesinos, Rosario Palacios, María A Gómez-Vidal, Juan Macías, Juan A Pineda, Nicolás Merchante, Pilar Rincón, María Iglesias, Luis M Real, Juan Macías, Juan A Pineda, Antonio Rivero Juárez, Teresa Brieva, Angela Camacho Espejo, Antonio Rivero, Francisco Téllez, Dolores Merino, Miguel Raffo, María J Ríos Villegas, Inmaculada López Montesinos, Marina Villalobos, Rosario Palacios, Jesús Santos, Mohamed Omar, Maria A Gómez Vidal, Monserrat Pérez Pérez. Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis. Journal of Antimicrobial Chemotherapy 2018; 73(9): 2435 doi: 10.1093/jac/dky234
|
| 43 |
Amit G. Singal, Michael L. Volk, Donald Jensen, Adrian M. Di Bisceglie, Philip S. Schoenfeld. A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C Virus. Clinical Gastroenterology and Hepatology 2010; 8(3): 280 doi: 10.1016/j.cgh.2009.11.018
|
| 44 |
Aaron Cohn, Andrew Aronsohn. HCV Therapy: Treat now or wait?. Current Hepatitis Reports 2013; 12(1): 7 doi: 10.1007/s11901-013-0163-9
|
| 45 |
Nicolás Merchante, Francisco Rodríguez-Arrondo, Boris Revollo, Esperanza Merino, Sofía Ibarra, María J. Galindo, Marta Montero, Miguel García-Deltoro, Antonio Rivero-Juárez, Francisco Téllez, Marcial Delgado-Fernández, María J. Ríos-Villegas, María A. García, Francisco J. Vera-Méndez, Guillermo Ojeda-Burgos, Miguel A. López-Ruz, Luis Metola, Mohamed Omar, María Remedios Alemán-Valls, Koldo Aguirrebengoa, Joseba Portu, Miguel Raffo, Juan Macías, Juan A. Pineda. Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients. AIDS 2018; 32(11): 1423 doi: 10.1097/QAD.0000000000001809
|
| 46 |
Soo Aleman, Nogol Rahbin, Ola Weiland, Loa Davidsdottir, Magnus Hedenstierna, Nina Rose, Hans Verbaan, Per Stål, Tony Carlsson, Hans Norrgren, Anders Ekbom, Fredrik Granath, Rolf Hultcrantz. A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C–Associated Liver Cirrhosis. Clinical Infectious Diseases 2013; 57(2): 230 doi: 10.1093/cid/cit234
|
| 47 |
Andrew J. Muir. Understanding the Complexities of Cirrhosis. Clinical Therapeutics 2015; 37(8): 1822 doi: 10.1016/j.clinthera.2015.05.507
|
| 48 |
Gamal Esmat, Maissa El Raziky. Cirrhosis: A practical guide to management. 2015; : 274 doi: 10.1002/9781118412640.ch24
|
| 49 |
Gisèle Nkontchou, Mounir Aout, Amel Mahmoudi, Dominique Roulot, Valérie Bourcier, Véronique Grando-Lemaire, Nathalie Ganne-Carrie, Jean-Claude Trinchet, Eric Vicaut, Michel Beaugrand. Effect of Long-term Propranolol Treatment on Hepatocellular Carcinoma Incidence in Patients with HCV-Associated Cirrhosis. Cancer Prevention Research 2012; 5(8): 1007 doi: 10.1158/1940-6207.CAPR-11-0450
|
| 50 |
Ashwani K. Singal, Amanpal Singh, Sathya Jaganmohan, Praveen Guturu, Rajasekhara Mummadi, Yong–Fang Kuo, Gagan K. Sood. Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in Patients With Hepatitis C Virus–Related Cirrhosis. Clinical Gastroenterology and Hepatology 2010; 8(2): 192 doi: 10.1016/j.cgh.2009.10.026
|
| 51 |
Lars Haukali Omland, Peer Brehm Christensen, Henrik Krarup, Peter Jepsen, Nina Weis, Henrik Toft Sørensen, Niels Obel, Heiner Wedemeyer. Mortality among Patients with Cleared Hepatitis C Virus Infection Compared to the General Population: A Danish Nationwide Cohort Study. PLoS ONE 2011; 6(7): e22476 doi: 10.1371/journal.pone.0022476
|
| 52 |
Angelo Alves de Mattos, Ângelo Zambam de Mattos. Treatment of HCV infection in patients with cirrhosis. Annals of Hepatology 2010; 9: S80 doi: 10.1016/S1665-2681(19)31729-6
|
| 53 |
Chang Seok Bang, Il Han Song. Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis. BMC Gastroenterology 2017; 17(1) doi: 10.1186/s12876-017-0606-9
|
| 54 |
Paulo R. Lerias de Almeida, Angelo Alves de Mattos, Cristiane Valle Tovo. Sustained virological response according to the type of early virological response in HCV and HCV/HIV. Annals of Hepatology 2010; 9(2): 150 doi: 10.1016/S1665-2681(19)31653-9
|
| 55 |
Ivan Gentile, Guglielmo Borgia. Surrogate endpoints and non-inferiority trials in chronic viral hepatitis. Journal of Hepatology 2010; 52(5): 778 doi: 10.1016/j.jhep.2009.12.023
|
| 56 |
Angelo Iacobellis, Francesco Perri, Maria Rosa Valvano, Nazario Caruso, Grazia Anna Niro, Angelo Andriulli. Long-Term Outcome After Antiviral Therapy of Patients With Hepatitis C Virus Infection and Decompensated Cirrhosis. Clinical Gastroenterology and Hepatology 2011; 9(3): 249 doi: 10.1016/j.cgh.2010.10.036
|
| 57 |
Ivan Gentile, Maria Aurora Carleo, Federico Borgia, Giuseppe Castaldo, Guglielmo Borgia. The efficacy and safety of telaprevir – a new protease inhibitor against hepatitis C virus. Expert Opinion on Investigational Drugs 2010; 19(1): 151 doi: 10.1517/13543780903501505
|
| 58 |
Fabio Salvatore Macaluso, Vincenza Calvaruso, Antonio Craxì. Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eye. Future Microbiology 2015; 10(6): 977 doi: 10.2217/fmb.15.31
|
| 59 |
Mario Frías, Antonio Rivero-Juárez, Isabel Machuca, Ángela Camacho, Antonio Rivero. The outlook for precision medicine for the treatment of chronic hepatitis C infection: challenges and opportunities. Expert Review of Precision Medicine and Drug Development 2020; 5(4): 253 doi: 10.1080/23808993.2020.1764346
|
| 60 |
Serda Gulsun, Recep Tekin, Fatma Bozkurt. Treatment of Chronic Delta Hepatitis: A Nine-Year Retrospective Analysis. Hepatitis Monthly 2011; 11(9): 731 doi: 10.5812/kowsar.1735143X.2462
|
| 61 |
Gennaro D’Amico, Giovanni Perricone. Prediction of Decompensation in Patients with Compensated Cirrhosis: Does Etiology Matter?. Current Hepatology Reports 2019; 18(2): 144 doi: 10.1007/s11901-019-00473-1
|
| 62 |
Tatsuo Kanda, Osamu Yokosuka, Masao Omata. Treatment of hepatitis C virus infection in the future. Clinical and Translational Medicine 2013; 2(1) doi: 10.1186/2001-1326-2-9
|
| 63 |
Xiuzhu Gao, Mengru Zhan, Liquan Wang, Yanhua Ding, Junqi Niu. <p>Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC</p>. Journal of Hepatocellular Carcinoma 2020; : 347 doi: 10.2147/JHC.S279657
|
| 64 |
Katsuhisa Nakatsuka, Masanori Atsukawa, Masumi Shimizu, Hidemi Takahashi, Chiaki Kawamoto. Ribavirin contributes to eradicate hepatitis C virus through polarization of T helper 1/2 cell balance into T helper 1 dominance. World Journal of Hepatology 2015; 7(25): 2590-2596 doi: 10.4254/wjh.v7.i25.2590
|
| 65 |
X. Wang, F. Gao, G. Yuan, K. Shi, Y. Huang, Y. Chen, R. Qiu, L. Sun, J. Liu, C. Hu, Y. Zhou. Ten‐year follow‐up analysis of chronic hepatitis C patients after getting sustained virological response to pegylated interferon‐α and ribavirin therapy. Journal of Viral Hepatitis 2016; 23(12): 971 doi: 10.1111/jvh.12574
|